Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Leases (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Operating Leases data on record, last reported at $36.7 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 15.16% year-over-year to $36.7 million; the TTM value through Sep 2025 reached $36.7 million, down 15.16%, while the annual FY2024 figure was $39.6 million, 8.28% down from the prior year.
  • Operating Leases reached $36.7 million in Q3 2025 per ZNTL's latest filing, down from $37.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $47.0 million in Q1 2023 and bottomed at $36.7 million in Q3 2025.
  • Average Operating Leases over 4 years is $42.5 million, with a median of $43.6 million recorded in 2023.
  • Peak YoY movement for Operating Leases: changed 0.0% in 2024, then dropped 15.16% in 2025.
  • A 4-year view of Operating Leases shows it stood at $45.2 million in 2022, then fell by 4.46% to $43.2 million in 2023, then decreased by 8.28% to $39.6 million in 2024, then decreased by 7.25% to $36.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $36.7 million in Q3 2025, $37.7 million in Q2 2025, and $38.7 million in Q1 2025.